Coloplast is rated a 'Buy' as it trades about 20% below its intrinsic value despite recent challenges including a DKK 3 billion impairment and currency headwinds affecting Q2 results. The company posted 6% organic growth in Q2-25/26 and management expects 5-6% organic revenue growth and 5% EBIT growth for the full year. Long-term targets include 7-8% annual organic growth and over 20% return on invested capital by FY29/30, supported by aging populations and emerging market expansion. Risks remain around reimbursement and innovation, but structural tailwinds support the investment thesis.
Bitcoin's recent price recovery is supported by significant institutional investment, particularly through regulated ETFs, signaling a shift toward long-term ownership. Despite some volatility and a U.S. legislative setback on crypto regulation, infl...
The First Trust High Yield Opportunities 2027 Term Fund (FTHY) is experiencing near-term volatility and weak distribution coverage, with its discount widening despite an approaching liquidation date. However, the fund's term structure may lead to a v...
Glassnode's Altcoin Cycle Signal rose to 86 in June, indicating altcoins outperform Bitcoin, mainly due to Bitcoin's 18% drop rather than strong altcoin demand. By early July, the signal confirmed genuine altcoin strength, but by September, despite a...
The Bitwise Solana Staking ETF (BSOL) attracted over $60 million in new investments in the last two days, raising its assets under management to an all-time high of more than $1.2 billion. This surge reflects growing investor confidence in Solana's p...
Zappin, a new Telegram-based trading bot, launched on Robinhood Chain on September 21, allowing users to swap tokens via Uniswap and receive 90% of their trading fees back in ETH for 30 days. This promotion aims to attract early users to Robinhood's ...
